Item 1.01 Entry into a Material Definitive Agreement.
On June 15, 2021, Zai Lab US LLC, a wholly-owned subsidiary of Zai Lab Limited
(the "Company"), and MacroGenics, Inc. ("MacroGenics") entered into a
collaboration and license agreement (the "Agreement"), pursuant to which the
Company and MacroGenics agreed to collaboratively develop and commercialize up
to four bispecific antibody-based molecules based on the MacroGenics'
proprietary DART® and TRIDENT® multi-specific technology platforms. Under the
Agreement, each party agrees to contribute specified intellectual property to
enable the research, development, manufacture and commercialization of up to
four future CD3 or CD47-based bispecific molecules. The Company will be granted
exclusive rights in Greater China, Japan, and Korea for two programs and
exclusive global rights for two other programs.
Under the terms of the Agreement, for all four programs, MacroGenics will
receive an upfront payment of $25 million. Further, on June 15, 2021, as partial
consideration for the rights granted to the Company under the Agreement, the
Company entered into a stock purchase agreement (the "Stock Purchase Agreement")
with MacroGenics, pursuant to which the Company will purchase from MacroGenics
in a private placement an aggregate of 958,467 newly issued shares of common
stock, par value $0.01 per share, of MacroGenics (the "Shares"), with a per
share purchase price of $31.30 (the "Private Placement"), for aggregate gross
proceeds of approximately $30 million (collectively, the "Offering"). The
closing of the Offering is expected to occur by the end of the second quarter of
2021.
In addition, MacroGenics is eligible to receive up to $1.4 billion in potential
development, regulatory and commercial milestone payments. If products from the
collaboration are commercialized, MacroGenics would also receive tiered
royalties on annual net sales of specified products, subject to reduction under
specified circumstances. The Company also has an option to convert the royalty
arrangement for the lead research molecule to a global 50/50 profit and loss
sharing arrangement by making a payment of approximately $85 million.
The Agreement will generally terminate on a program-by-program and
country-by-country or region-by-region basis, with certain exceptions, upon the
later to occur of (i) the date that is 12 years after the date of the first
commercial sale of the product in the applicable country or region, (ii) the
date of expiration of the last valid claim covering such product with a licensed
patent in the applicable country or region and (iii) the expiration date of any
data exclusivity period for such product in the applicable country or region.
For certain programs, the Company may terminate the Agreement, in whole or in
part, after the second or fourth anniversary of the date of the Agreement by
providing 90 days' written notice to MacroGenics and, upon other conditions,
after the second anniversary of the date of the Agreement with 180 days' written
notice to MacroGenics. MacroGenics may terminate the Agreement on a
collaboration product-by-collaboration product upon 90 days' written notice if a
major safety issue has occurred with respect to a collaboration product. Either
party may terminate the Agreement upon a material breach by the other party that
remains uncured or upon certain bankruptcy events. In addition, MacroGenics may
terminate the Agreement if the Company challenges the licensed patent rights.
The foregoing descriptions of the terms of the Agreement and the Stock Purchase
Agreement do not purport to be complete and is qualified in its entirety by
reference to the full text of the Agreement and the Stock Purchase Agreement,
which the Company intends to file as exhibits to a subsequent periodic report or
on an amendment to this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
On June 16, 2021 (U.S. time), the Company issued a press release announcing the
above-described transactions. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed to be
"filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act or the Exchange Act, except as
expressly set forth by specific reference in such filing or this Current Report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press release issued on June 16, 2021.
104 The cover page of this Current Report on Form 8-K is formatted in
Inline XBRL
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses